Tempus AI, Inc.’s Quiet Period Will Expire Tomorrow (NASDAQ:TEM)

Tempus AI’s (NASDAQ:TEM) quiet period will expire on Wednesday, July 24th. Tempus AI had issued 11,100,000 shares in its initial public offering on June 14th. The total size of the offering was $410,700,000 based on an initial share price of $37.00. During Tempus AI’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

A number of research firms have commented on TEM. Needham & Company LLC began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a “buy” rating and a $47.00 price target on the stock. Morgan Stanley started coverage on Tempus AI in a research report on Tuesday, July 9th. They set an “overweight” rating and a $44.00 price target on the stock. Longbow Research began coverage on Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Tempus AI in a research note on Tuesday, July 9th. They issued an “overweight” rating and a $42.00 target price for the company. Finally, Stifel Nicolaus started coverage on shares of Tempus AI in a report on Tuesday, July 9th. They set a “buy” rating and a $45.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tempus AI has a consensus rating of “Buy” and an average target price of $45.63.

Tempus AI Stock Up 3.8 %

Shares of TEM stock opened at $42.98 on Tuesday. Tempus AI has a 12 month low of $22.89 and a 12 month high of $45.11.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.